AGENCY AGREEMENTAgency Agreement • July 5th, 2017 • IntelGenx Technologies Corp. • Pharmaceutical preparations
Contract Type FiledJuly 5th, 2017 Company IndustryThe undersigned, Desjardins Securities Inc. (the “Lead Agent”), Laurentian Bank Securities Inc. (“Laurentian”) and Echelon Wealth Partners Inc. (“Echelon” and, collectively with the Lead Agent and Laurentian, the “Agents” and each individually, an “Agent”) understand that IntelGenx Technologies Corp. (the “Corporation”) proposes to issue and offer for sale a minimum of $5,000,000 and a maximum of $10,000,000 aggregate principal amount of Debentures (as hereinafter defined) due June 30, 2020 (the “Maturity Date”) at a price of $1,000 per Debenture (the “Offering Price”). The Debentures will bear interest at an annual rate of 8% payable semi-annually on the last day of June and December of each year (or the immediately following business day if any interest payment date would not otherwise be a business day), commencing on December 31, 2017. The Debentures will be redeemable, in whole or in part, at the option of the Corporation and each Debenture will be convertible into common shares o
AGENCY AGREEMENTAgency Agreement • June 29th, 2017 • IntelGenx Technologies Corp. • Pharmaceutical preparations
Contract Type FiledJune 29th, 2017 Company IndustryThe undersigned, Desjardins Securities Inc. (the “Lead Agent”), Laurentian Bank Securities Inc. (“Laurentian”) and Echelon Wealth Partners Inc. (“Echelon” and, collectively with the Lead Agent and Laurentian, the “Agents” and each individually, an “Agent”) understand that IntelGenx Technologies Corp. (the “Corporation”) proposes to issue and offer for sale a minimum of $5,000,000 and a maximum of $10,000,000 aggregate principal amount of Debentures (as hereinafter defined) due June 30, 2020 (the “Maturity Date”) at a price of $1,000 per Debenture (the “Offering Price”). The Debentures will bear interest at an annual rate of 8% payable semi-annually on the last day of June and December of each year (or the immediately following business day if any interest payment date would not otherwise be a business day), commencing on December 31, 2017. The Debentures will be redeemable, in whole or in part, at the option of the Corporation and each Debenture will be convertible into common shares o